Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Double or nothing on cancer immunotherapy

Nature Biotechnology volume 31, pages 33–34 (2013)Cite this article

Subjects

Engineered T cells expressing two receptors distinguish malignant cells from healthy cells even in the absence of a tumor-specific antigen.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Strategy for designing T cells to attack tumor cells and spare normal tissues.

References

  1. Restifo, N., Dudley, M. & Rosenberg, S. Nat. Rev. Immunol. 12, 269–281 (2012).

    Article  CAS  Google Scholar 

  2. Davila, M.L., Brentjens, R.J., Wang, X., Riviere, I. & Sadelain, M. OncoImmunology 1, 1577–1583 (2012).

    Article  Google Scholar 

  3. Kloss, C.C., Condomines, M., Cartellieri, M., Bachmann, M. & Sadelain, M. Nat. Biotechnol. 30, 71–75 (2013).

    Article  Google Scholar 

  4. Robbins, P. et al. J. Clin. Oncol. 29, 917–924 (2011).

    Article  Google Scholar 

  5. Porter, D., Levine, B., Kalos, M., Bagg, A. & June, C. N. Engl. J. Med. 365, 725–733 (2011).

    Article  CAS  Google Scholar 

  6. Brentjens, R. et al. Blood 118, 4817–4828 (2011).

    Article  CAS  Google Scholar 

  7. Kochenderfer, J. et al. Blood 119, 2709–2720 (2012).

    Article  CAS  Google Scholar 

  8. Morgan, R.A. et al. Mol. Ther. 18, 843–851 (2010).

    Article  CAS  Google Scholar 

  9. Morgan, R.A. et al. J. Immunother. (in the press).

  10. Duong, C.P., Westwood, J.A., Berry, L.J., Darcy, P.K. & Kershaw, M.H. Immunotherapy 3, 33–48 (2011).

    Article  CAS  Google Scholar 

  11. Wilkie, S. et al. J. Clin. Immunol. 32, 1059–1070 (2012).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Ken-ichi Hanada and Nicholas P. Restifo are in the Center for Cancer Research, National Cancer Institute, US National Institutes of Health, Bethesda, Maryland, USA.,

    Ken-ichi Hanada & Nicholas P Restifo

Authors
  1. Ken-ichi Hanada
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Nicholas P Restifo
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Nicholas P Restifo.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hanada, Ki., Restifo, N. Double or nothing on cancer immunotherapy. Nat Biotechnol 31, 33–34 (2013). https://doi.org/10.1038/nbt.2471

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nbt.2471

This article is cited by

Search

Advanced search

Quick links

Nature Briefing: Translational Research

Sign up for the Nature Briefing: Translational Research newsletter — top stories in biotechnology, drug discovery and pharma.

Get what matters in translational research, free to your inbox weekly. Sign up for Nature Briefing: Translational Research